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abstract
PURPOSE In the HER2CLIMB study, patients with human epidermal growth factor receptor 2 (HER2)–positive
breast cancer with brain metastases (BMs) showed statistically significant improvement in progression-free
survival (PFS) with tucatinib. We describe exploratory analyses of intracranial efficacy and survival in participants
with BMs.
PATIENTS AND METHODS Patients were randomly assigned 2:1 to tucatinib or placebo, in combination with
trastuzumab and capecitabine. All patients underwent baseline brain magnetic resonance imaging; those with
BMs were classified as active or stable. Efficacy analyses were performed by applying RECIST 1.1 criteria to CNS
target lesions by investigator assessment. CNS-PFS (intracranial progression or death) and overall survival (OS)
were evaluated in all patients with BMs. Confirmed intracranial objective response rate (ORR-IC) was evaluated
in patients with measurable intracranial disease.
RESULTS There were 291 patients with BMs: 198 (48%) in the tucatinib arm and 93 (46%) in the control arm.
The risk of intracranial progression or death was reduced by 68% in the tucatinib arm (hazard ratio [HR], 0.32;
95% CI, 0.22 to 0.48; P, .0001). Median CNS-PFS was 9.9 months in the tucatinib arm versus 4.2 months in
the control arm. Risk of death was reduced by 42% in the tucatinib arm (OSHR, 0.58; 95%CI, 0.40 to 0.85; P5
.005). Median OS was 18.1 versus 12.0 months. ORR-IC was higher in the tucatinib arm (47.3%; 95% CI,
33.7% to 61.2%) versus the control arm (20.0%; 95% CI, 5.7% to 43.7%; P 5 .03).
CONCLUSION In patients with HER2-positive breast cancer with BMs, the addition of tucatinib to trastuzumab
and capecitabine doubled ORR-IC, reduced risk of intracranial progression or death by two thirds, and reduced
risk of death by nearly half. To our knowledge, this is the first regimen to demonstrate improved antitumor activity
against BMs in patients with HER2-positive breast cancer in a randomized, controlled trial.
J Clin Oncol 38. © 2020 by American Society of Clinical Oncology
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INTRODUCTION
Up to 50% of patients with human epidermal growth
factor receptor 2 (HER2)–positive metastatic breast
cancer will develop brain metastases (BMs) during
the course of their disease.1-5 Initial therapy for BMs
typically consists of locally directed therapy with
surgical resection, stereotactic radiosurgery, and/or
whole-brain radiation therapy.6 Unfortunately, the rate
of intracranial progression within 6 to 12 months with
these therapies is high.7-9 In the absence of ran-
domized, prospective data demonstrating a benefit of
switching systemic agents at the time of brain pro-
gression, ASCO clinical practice guidelines currently
recommend that patients with stable systemic disease
at the time of brain progression continue treatment
with the same systemic treatment after local therapy
and until further progression.6 In patients whose BMs
have progressed after radiation therapy, the limited
evidence to guide further management consists pri-
marily of nonrandomized case series describing treated-
lesion control, intracranial control, and overall survival
(OS), without detailed descriptions of extracranial out-
comes or concurrent systemic therapy.10-12
Patients with untreated or treated and progressing (ie,
active) BMs have traditionally been excluded from
participation in most clinical trials evaluating sys-
temic HER2-targeting regimens.13,14 Recently reported
progression-free survival (PFS) in lapatinib-na ı̈ve
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(n 5 37) or lapatinib-treated patients (n 5 12) with
progressive CNS disease treated with neratinib plus
capecitabine was 5.5 and 3.1 months, respectively,15
similar to the 3.6 months previously reported for lapatinib
plus capecitabine in patients with progressive CNS disease.16
At the time HER2CLIMB was designed, there were no
approved systemic treatments for breast cancer patients
with active brain metastases.
Penetration across an intact blood-brain barrier is assumed
to be limited with antibody-based anti-HER2 agents, such
as trastuzumab, pertuzumab, and antibody-drug conju-
gates.17 Small-molecule HER2 kinase inhibitors have the
potential to penetrate the brain more effectively. Tucatinib
is a small-molecule oral tyrosine kinase inhibitor (TKI) that
is highly selective for HER2, with demonstrated antitumor
activity alone and in combination with other HER2-targeting
agents.18 A phase Ib trial evaluating tucatinib plus trastu-
zumab in patients with active HER2-positive BMs provided
preliminary evidence of intracranial activity (objective re-
sponses and prolonged clinical benefit), including in pa-
tients with prior lapatinib and/or neratinib exposure.19
Another phase Ib trial reported intracranial response in 5
of 12 patients with active HER2-positive CNS disease treated
with tucatinib with trastuzumab and/or capecitabine.20
The HER2CLIMB randomized, double-blind, placebo-
controlled trial compared tucatinib versus placebo in com-
bination with trastuzumab and capecitabine in patients with
HER2-positive metastatic breast cancer previously treated
with trastuzumab, pertuzumab, and T-DM1.21 The trial was
unique in that it enrolled a large proportion (48%) of pa-
tients with BMs, including previously untreated, treated
stable, and treated and progressing BMs. HER2CLIMB
demonstrated clinically meaningful and statistically sig-
nificant improvements in OS, PFS, and confirmed objective
response rate (ORR) in all patients treated with tucatinib,
trastuzumab, and capecitabine.21 Based in large part on the
HER2CLIMB results, tucatinib was approved by the FDA in
April 2020 for use in combination with trastuzumab and
capecitabine in patients with and without brain metastases
who have received one or more prior anti-HER2–based
regimens in the metastatic setting. Importantly, HER2CLIMB
was the first randomized trial to our knowledge to demon-
strate a statistically significant and clinically meaningful
improvement in PFS among patients with BMs. We report
exploratory analyses of the intracranial and OS outcomes
in HER2CLIMB patients with BMs.
PATIENTS AND METHODS
Study Design
The design of the HER2CLIMB trial has been described
previously.21 Patients age $ 18 years with centrally con-
firmed, locally advanced or metastatic HER2-positive
breast carcinoma previously treated with trastuzumab,
pertuzumab, and T-DM1 were randomly assigned 2:1 by
minimization to receive either tucatinib or placebo in com-
bination with trastuzumab and capecitabine (Appendix Fig
A1, online only). Patients were stratified based upon pres-
ence or absence of BM, Eastern Cooperative Oncology
Group performance status score (0 or 1), and geographic
region (North America [Canada, n5 32] or rest of the world).
The trial was conducted in accordance with regulatory re-
quirements and International Conference on Harmonisation
Good Clinical Practice guidelines. The study protocol was
approved by institutional review boards and ethics com-
mittees, and all patients provided written informed consent.
Assessment and Classification of BMs
All HER2CLIMB patients had magnetic resonance imaging
(MRI) of the brain at baseline. Patients with BMs on the
baseline scan had a contrast-enhanced brain MRI every
6 weeks for 24 weeks and every 9 weeks thereafter. BMs
at enrollment were classified as treated and stable (prior
CONTEXT
Key Objective
To explore the impact of tucatinib, when combined with trastuzumab and capecitabine, on intracranial efficacy and survival
in patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer and brain me-
tastases (BMs) in the randomized HER2CLIMB clinical trial.
Knowledge Generated
Among 291 enrolled patients with BMs, the addition of tucatinib to trastuzumab and capecitabine doubled the intracranial
objective response rate (47.3% v 20.0%; P 5 .03), reduced the risk of intracranial progression or death by two thirds
(hazard ratio [HR], 0.32; 95% CI, 0.22 to 0.48; P , .0001), and reduced the risk of death by nearly half (HR, 0.58;
95% CI, 0.40 to 0.85; P 5 .005).
Relevance
The combination of tucatinib, trastuzumab, and capecitabine is the first systemic therapy to our knowledge to demonstrate
clinically meaningful benefits, including prolongation of survival, in patients with HER2-positive breast cancer who have
either stable or active BMs in the context of a prospective, randomized clinical trial.
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local treatment and no evidence of progression at baseline
brain MRI, including patients treated during the screen-
ing period), treated and progressing (prior local treatment
but evidence of progression of existing lesions, new le-
sions, or untreated lesions remaining after prior treatment
at baseline brain MRI), or untreated (no prior local treat-
ment). Patients with BMs were allowed up to 2 mg of
dexamethasone per day (or equivalent) for control of BM
symptoms. Patients with untreated brain lesions . 2 cm
could enroll if immediate local therapy was not required per
investigator assessment of factors such as size, location,
and symptoms. Patients who required immediate local
therapy based on new findings on the screening brain MRI
could still enroll after receiving radiation therapy or surgery
and completing a mandated washout period; these patients
were included in the treated stable group for this analysis
and were not considered to have measurable disease as-
sessable for intracranial response. Patients with leptomening-
eal disease were excluded.
Efficacy Assessments
Disease response and progression in the brain were
evaluated by applying RECIST 1.122 to assess brain le-
sions in isolation from other organs based on investigator
assessment. Intracranial response was derived from the
change in the sum of diameters of all target brain lesion
measurements as well as consideration of nontarget and
new brain lesions, using RECIST 1.1 response and pro-
gression thresholds.22
TABLE 1. Demographic and Disease Characteristics of HER2CLIMB Patients With BMs
Characteristic
No. (%)
Tucatinib, Trastuzumab,
and Capecitabine (n 5 198)
Placebo, Trastuzumab,
and Capecitabine (n 5 93)
Total
(N 5 291)
Age, years
Median 53 52 52
Range 22-75 25-75 22-75
, 65 166 (83.8) 77 (82.8) 243 (83.5)
$ 65 32 (16.2) 16 (17.2) 48 (16.5)
Female sex 197 (99.5) 92 (98.9) 289 (99.3)
Geographic region
North America (US and Canada) 116 (58.6) 61 (56.6) 177 (60.8)
Rest of the world 82 (41.4) 32 (34.4) 114 (39.2)
ECOG performance status scorea
0 92 (46.5) 38 (40.9) 130 (44.7)
1 106 (53.5) 55 (59.1) 161 (55.3)
Histology
Estrogen and/or progesterone receptor positive 107 (54.0) 59 (63.4) 166 (57.0)
Estrogen and progesterone receptor negative 88 (44.4) 34 (36.6) 122 (41.9)
Metastatic at initial diagnosis 77 (38.9) 39 (41.9) 116 (39.9)
Non-CNS metastatic disease 192 (97.0) 90 (96.8) 282 (96.9)
BM treatment status at baseline
Treated and stableb 80 (40.4) 37 (39.8) 117 (40.2)
Treated and progressingc 74 (37.4) 34 (36.6) 108 (37.1)
Untreatedd 44 (22.2) 22 (23.7) 66 (22.7)
Prior therapy for BMs
Radiation therapy 140 (70.7) 64 (68.8) 204 (70.1)
WBRT 77 (38.9) 45 (48.4) 122 (41.9)
Targeted radiation therapy 92 (46.5) 32 (34.4) 124 (42.6)
Surgery 33 (16.7) 13 (14.0) 46 (15.8)
Abbreviations: BM, brain metastasis; ECOG, Eastern Cooperative Oncology Group; WBRT, whole-brain radiation therapy.
aECOG performance status scores range from 0 to 5, with higher score indicating greater disability.
bAll BMs previously treated with surgery/radiation therapy, without subsequent documented progression of BMs.
cPreviously treated with surgery/radiation therapy with any documented progression of BMs since most recent surgery/radiation therapy treatment of BMs.
dNo prior surgery/radiation therapy for BMs.
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The following end points were considered exploratory:
confirmed intracranial ORR (ORR-IC) and duration of in-
tracranial response (DOR-IC) in patients with measurable
intracranial lesions at baseline and CNS-PFS, defined as
time from random assignment to disease progression in the
brain or death resulting from any cause, whichever oc-
curred first. DOR-IC was defined as the time from first
intracranial objective response (confirmed complete or
partial) to documented intracranial disease progression or
death resulting from any cause, whichever occurred first.
Analyses were performed for these exploratory end points
for all patients with BMs and then separately for those with
stable BMs and those with active BMs. The active BM
group consisted of patients with untreated or treated and
progressing BMs, consistent with the 2019 US Food and
Drug Administration (FDA) guidance “Cancer Clinical
Trial Eligibility Criteria: Brain Metastases—Guidance for
Industry.”13 OS by treatment arm was also evaluated in
these subgroups.
Patients with progressive disease per RECIST 1.1 isolated to
the brain were eligible to continue study-assigned therapy
after local treatment until second progression at any site.
These patients were considered to have progressive dis-
ease for the purposes of the primary end point. Time from
random assignment to second progression in the brain or
body or death was reported for patients with isolated brain
progression who continued study-assigned treatment after
local treatment of BMs.
Statistical Analysis
Kaplan-Meier methodology was used to estimate CNS-PFS,
OS, and time to second progression curves and their
95%CIs. For CNS-PFS and OS, a stratified Cox proportional
hazards model was used to estimate hazard ratios (HRs)
and 95% CIs. For time to second progression analysis, the
HR from the unstratified Cox proportional hazards model
was estimated because of the small number of patients. All
P values reported are nominal and were obtained from the
stratified log-rank test.
The confirmed ORR-IC with exact 95% CI was provided
for patients with measurable intracranial disease at
baseline by treatment arm. Comparison of ORR-IC be-
tween treatment arms was performed using a 2-sided
Cochran-Mantel-Haenszel test, controlling for the afore-
mentioned stratification factors. Among patients who
achieved a confirmed ORR-IC, Kaplan-Meier estimates of
median DOR-IC (corresponding 95% CIs) were provided
for each treatment arm. The same censoring scheme and
methods for the primary analysis of PFS were used for
the DOR-IC analysis.
RESULTS
Patient Characteristics
Of 612 patients enrolled in the HER2CLIMB trial, 291
(48%) had BMs at baseline or a history of BMs: 198 (48%)
in the tucatinib arm and 93 (46%) in the control arm.
Median time from diagnosis of metastatic disease to
development of BMs was 13.0 months (range, , 0.1 to
100.7 months) and 9.8 months (range, , 0.1 to 172.7
months), respectively. Median time from first diagnosis of
BMs to study enrollment was 15.8 months (range, 1.1 to
169.2 months) and 14.5 months (range, 0.5 to 99.3
months), respectively.
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FIG 1. Kaplan-Meier curves for patients with brain metastases. (A) CNS progression-free survival (CNS-PFS) per investigator assessment. (B) Overall survival
(OS). Hazard ratio (HR) computed from the Cox proportional hazards model using stratification factors (Eastern Cooperative Oncology Group performance
status [0 or 1], region of world [North America or rest of world]) at random assignment. Two-sided P value calculated from stratified log-rank test.
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Baseline demographic and disease characteristics were
well balanced between treatment arms (Table 1) and
similar to the overall HER2CLIMB population.21 Eighty
patients (40.4%) in the tucatinib arm and 37 (39.8%) in the
control arm had stable BMs at baseline. Active BMs (in-
cluding untreated and treated progressing BMs) were
identified in 118 (59.6%) and 56 patients (60.2%), re-
spectively. Nearly all patients with BMs also had disease
outside of the brain (approximately 97% in both arms).
Efficacy in All Patients With BMs
Among the 291 patients with BMs, estimated 1-year CNS-
PFS was 40.2% (95% CI, 29.5% to 50.6%) in the tucatinib
arm and 0% in the control arm. Risk of progression in the
brain or death was reduced by 68% in the tucatinib arm
versus the control arm (HR, 0.32; 95% CI, 0.22 to 0.48;
P , .0001; Fig 1A). Median duration of CNS-PFS was
9.9 months (95% CI, 8.0 to 13.9 months) in the tucatinib
arm and 4.2 months (95% CI, 3.6 to 5.7 months) in the
control arm. Estimated 1-year OS was 70.1% (95% CI,
62.1% to 76.7%) in the tucatinib arm and 46.7% (95% CI,
33.9% to 58.4%) in the control arm. Risk of death was
reduced by 42% in the tucatinib arm versus the control arm
(HR, 0.58; 95%CI, 0.40 to 0.85; P5 .005; Fig 1B). Median
time to death resulting from any cause was 18.1 months
(95% CI, 15.5 months to not estimable) in the tucatinib arm
versus 12.0 months (95% CI, 11.2 to 15.2 months) in the
control arm.
Efficacy in Patients With Active BMs
Among the 174 patients with active BMs, estimated 1-year
CNS-PFS was 35.0% (95% CI, 23.2% to 47.0%) in the
tucatinib arm and 0% in the control arm. Risk of pro-
gression in the brain or death was reduced by 64% in
the tucatinib arm versus the control arm (HR, 0.36;
95% CI, 0.22 to 0.57; P, .0001; Fig 2A). Median duration
of CNS-PFS was 9.5 months (95% CI, 7.5 to 11.1 months)
in the tucatinib arm and 4.1 months (95% CI, 2.9 to
5.6 months) in the control arm. Estimated 1-year OS was
71.7% (95% CI, 61.4% to 79.7%) in the tucatinib arm
and 41.1% (95% CI, 25.5% to 56.1%) in the control arm.
Risk of death was reduced by 51% in the tucatinib arm
versus the control arm (HR, 0.49; 95% CI, 0.30 to 0.80;
P5 .004; Fig 2B). Median duration of OS was 20.7 months
(95% CI, 15.1 months to not estimable [because of the
censored largest observed time]) in the tucatinib arm
and 11.6 months (95% CI, 10.5 to 13.8 months) in the
control arm.
Among the 75 patients with active BMs and measurable
intracranial disease at baseline, the confirmed ORR-IC was
47.3% (95% CI, 33.7% to 61.2%) in the tucatinib arm
versus 20.0% (95% CI, 5.7% to 43.7%) in the control arm
(P 5 .03; Table 2). In these patients, median DOR-IC was
6.8 months (95% CI, 5.5 to 16.4 months) in the tucatinib
arm versus 3.0 months (95% CI, 3.0 to 10.3 months) in
the control arm (Table 2). Estimated proportion of patients
with a response lasting 6 or 12months was 72.7% (95%CI,
48.9% to 86.8%) and 28.3% (95% CI, 8.0% to 53.2%),
respectively, in the tucatinib arm compared with 25.0%
(95% CI, 0.9% to 66.5%) and 0%, respectively, in the
control arm.
A subset of patients (44 in the tucatinib arm and 22 in the
control arm) entered the study with active, untreated BMs and
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FIG 2. Kaplan-Meier curves for patients with active brain metastases. (A) CNS progression-free survival (CNS-PFS) per investigator assessment. (B) Overall
survival (OS). Hazard ratio (HR) computed from the Cox proportional hazards model using stratification factors (Eastern Cooperative Oncology Group
performance status [0 or 1], region of world [North America or rest of world]) at random assignment. Two-sided P value calculated from stratified log-
rank test.
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elected to defer radiation therapy in favor of systemic therapy.
Among these patients, CNS-PFS (medians, 8.1 v 3.1months),
ORR-IC (47.1% v 16.7%), and OS (median, 16.5 v 11.2
months) all favored the tucatinib arm (Data Supplement).
Efficacy in Patients With Stable BMs
Among the 117 patients with stable BMs, estimated 1-year
CNS-PFS was 53.3% (95% CI, 31.4% to 71.0%) in the
tucatinib arm and 0% in the control arm. Risk of progression
in the brain or death was reduced by 69% in the tucatinib
arm versus the control arm (HR, 0.31; 95% CI, 0.14 to 0.67;
P 5 .002; Fig 3A). Median duration of CNS-PFS was
13.9 months (95% CI, 9.7 to 32.2 months) in the tucatinib
arm and 5.6 months (95% CI, 3.0 to 9.5 months) in the
control arm. Estimated 1-year OS was 67.6% (95% CI,
53.8% to 78.0%) in the tucatinib arm and 55.6% (95% CI,
34.1% to 72.6%) in the control arm. Risk of death was nu-
merically lower in the tucatinib arm versus the control arm
(HR, 0.88; 95% CI; 0.45 to 1.70; P 5 .696; Fig 3B). Me-
dian duration of OS was 15.7 months (95% CI, 13.8 months
to not estimable) in the tucatinib arm and 13.6 months
(95% CI, 10.2 to 22.0 months) in the control arm.
Second Progression
Thirty patients (21 in the tucatinib arm and 9 in the control
arm) experienced isolated progression in the brain and
underwent local therapy followed by continued study-
assigned treatment (Fig 4A). In these patients, median
time from random assignment to second progression
(brain or body) or death was 15.9 months (95% CI, 11.7 to
28.2months) in the tucatinib arm and 9.7 months (95% CI,
4.9 to 12.0 months) in the control arm (HR, 0.29; 95% CI,
0.11 to 0.77; P 5 .009; Fig 4B). Median time from pro-
gression in the brain to second progression (brain or body)
or death in these patients was 7.6 months (95% CI, 3.9 to
11.3 months) in the tucatinib arm versus 3.1 months
(95% CI, 1.2 to 4.1 months) in the control arm (HR, 0.33;
95% CI, 0.13 to 0.85; P 5 .02; Fig 4C).
DISCUSSION
To our knowledge, HER2CLIMB is the only double-blind,
randomized study in patients with HER2-positive meta-
static breast cancer previously treated with trastuzumab,
pertuzumab, and T-DM1 to demonstrate a statistically
significant and clinically meaningful improvement in PFS
among patients with BMs, including those with active
BMs.21 Importantly, the longer PFS with tucatinib in the
overall population of patients with BMs was achieved via
control of both intracranial and extracranial disease.
The brain-specific analyses presented here, although
exploratory, were conducted in 291 randomly assigned
TABLE 2. Intracranial Confirmed Objective Response per Investigator in Patients With Active BMs and Measurable Intracranial Lesions at Baseline
Response
No. (%)
Tucatinib, Trastuzumab, and
Capecitabine (n 5 55)
Placebo, Trastuzumab, and
Capecitabine (n 5 20)
Best overall intracranial responsea
CR 3 (5.5) 1 (5.0)
PR 23 (41.8) 3 (15.0)
SD 24 (43.6) 16 (80.0)
PD 2 (3.6) 0
Not availableb 3 (5.5) 0
Objective response of confirmed CR or PR 26 4
ORR-IC, % 47.3 20.0
95% CIc 33.7 to 61.2 5.7 to 43.7
Stratified P d .03
DOR-IC, monthse 6.8 3.0
95% CIf 5.5 to 16.4 3.0 to 10.3
Abbreviations: CR, complete response; DOR-IC, duration of intracranial response; ORR-IC, confirmed intracranial objective response rate; PD,
progressive disease; PR, partial response; SD, stable disease.
aConfirmed best overall response assessed per RECIST 1.1.
bPatients with no postbaseline response assessments.
cTwo-sided 95% exact CI, computed using the Clopper-Pearson method.24
dCochran-Mantel-Haenszel test controlling for stratification factors (Eastern Cooperative Oncology Group performance status [0 or 1], region of
world [North America or rest of the world]) at random assignment.
eAs estimated using Kaplan-Meier method.
fCalculated using the complementary log-log transformation method.25
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patients with BMs and demonstrate clinically meaning-
ful intracranial activity of tucatinib. Nearly half of patients
with measurable, active BMs experienced a confirmed
intracranial response, demonstrating direct activity of the
tucatinib-based combination against BMs. In addition,
across all enrolled patients with BMs, tucatinib significantly
reduced the risk of intracranial progression or death by
68% compared with trastuzumab and capecitabine. This is
the first double-blind, randomized trial of systemic therapy
to our knowledge to demonstrate clinically meaningful
gains in OS among patients with BMs, including those with
active metastases, with a 42% reduction in the risk of death
and prolongation of median OS by. 6 months. Median OS
of 18.1 months in these heavily pretreated patients with
BMs is notable and further supports the inclusion of pa-
tients with CNS metastases in future breast cancer trials.
A unique subset was the group of 66 patients with un-
treated BMs who elected to enter HER2CLIMB in lieu of
radiation therapy. Although the overall numbers were small,
median CNS-PFS was 8.1 months in the tucatinib arm,
suggesting this strategy merits further exploration, because
it may delay the need for radiation therapy.
As prespecified in the HER2CLIMB protocol, patients with
isolated progression in the brain could continue study-
assigned, blinded therapy after local management with
radiation therapy or surgery. Although only 30 patients
continued on trial after local therapy, median time from
progression in the brain to second progression (brain or
body) or death in these patients was 4.5 months longer in
the tucatinib arm compared with the control arm, sug-
gesting that continuation of tucatinib after cranial radiation
therapy may delay subsequent disease progression. This
was also seen in 2 prior phase Ib clinical trials of tucatinib,
where 11 patients with isolated progression of BMs after
treatment with tucatinib plus T-DM1 or tucatinib with or
without trastuzumab with or without capecitabine contin-
ued study-assigned treatment after CNS-directed therapy.
In those patients, median time after CNS-directed radi-
ation therapy for isolated brain progression to any second
event was 8.3 months.23 This observation warrants further
evaluation of continuing the tucatinib plus trastuzumab
plus capecitabine regimen after local treatment of isolated
CNS progression.
Strengths of this exploratory analysis are its sample size
of nearly 300 patients with BMs and its randomized,
prospective design. Because of the large number of pa-
tients with active BMs, intracranial outcomes between
arms could be readily evaluated. One potential criticism
is the use of RECIST 1.1 for evaluation of intracranial
response. Increasingly, Response Assessment in Neuro-
Oncology Brain Metastases (RANO-BM) criteria are being
incorporated into the design of BM trials. Both RECIST 1.1
and RANO-BM use unidimensional measurements of
target lesions, with $ 30% decrease in the sum of target
lesions required for partial response. The main differences
are the maximum number of CNS target lesions (2 v 5,
respectively) and incorporation of steroid use and neuro-
logic symptoms in RANO-BM. Although future studies
could retrospectively analyze archival image files and data
from case report forms to compare response rates by
RECIST 1.1 and RANO-BM, in the context of the statistically
significant and clinically meaningful OS benefit in favor of
B
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FIG 3. Kaplan-Meier curves for patients with stable brain metastases. (A) CNS progression-free survival (CNS-PFS) per investigator assessment. (B) Overall
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the tucatinib arm seen in HER2CLIMB, we believe that small
differences in response rates that could potentially arise using
different response criteria become less critical to identify.
Of note, both the ASCO–Friends of Cancer Research Brain
Metastases Working Group and the 2019 FDA “Cancer
Clinical Trial Eligibility Criteria: Brain Metastases—Guidance
for Industry” have recommended inclusion of patients
with treated stable and active BMs in clinical trials so that
results will be more applicable to this population with
high unmet need.13,14
Together with the HER2CLIMB primary analysis, these
results demonstrate that tucatinib in combination with
trastuzumab and capecitabine is an active regimen for
intracranial and extracranial disease in patients with HER2-
positive metastatic breast cancer. To our knowledge,
HER2CLIMB is the first randomized study to demonstrate
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improvement in intracranial response, CNS-PFS, and OS in
patients with HER2-positive breast cancer who have BMs,
including active lesions. Tucatinib is the first TKI to our
knowledge to demonstrate improved antitumor activity
against BMs in patients with HER2-positive breast cancer
in a randomized, controlled trial.
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APPENDIX
Patients screened 
(N = 819)
Allocated to tucatinib, 
trastuzumab, and capecitabine
(n = 410)
Allocated to placebo, 
trastuzumab, and capecitabine
(n = 202)
Excluded
(n = 207)
Randomly assigned
(n = 612)
2:1 random assignment
Without BMs
(n = 211)a
Without BMs
(n = 108)a
Remained on treatment
(n = 59)
Remained on treatment
(n = 11)
With BMs                      (n = 198)a
   Treated stable             (n = 80)
   Treated progressing   (n = 74)
   Untreated                    (n = 44)
With BMs                           (n = 93)a
   Treated stable                 (n = 37)
   Treated progressing      (n = 34)
   Untreated                        (n = 22)
FIG A1. CONSORT diagram. BM, brain metastasis. (a) Two enrolled patients did not undergo baseline brain
magnetic resonance imaging (1 in tucatinib arm and 1 in placebo arm).
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